On August 6, Cronos Group (NASDAQ:CRON) reported second quarter results that finally paired growth with profitability. Net revenue climbed 58% year over year to $53.0 million, but the number that stands out is the bottom line: net income of $35.7 million, compared with a $38.5 million loss a year earlier. The company also disclosed a fresh complication. One day earlier, on August 5, Israeli regulators notified Cronos of a new investigation into alleged dumping of Canadian cannabis imports, a threat aimed squarely at the market driving most of that growth.
A Quarter Built On Records
Every major line moved in the right direction. Gross profit nearly doubled, up 96% to $28.5 million, and gross margin expanded 11 percentage points to 54%, evidence that higher prices and fuller production lines are doing more than just growing the top line. Adjusted EBITDA jumped to $13.1 million from $1.7 million, a 675% increase suggesting the extra revenue is finally reaching the operating result instead of getting absorbed by costs.
Israel remains the engine. Cronos Israel logged its tenth consecutive quarter of record net revenue, up 60% year over year, with PEACE NATURALS holding its spot as the country’s top cannabis brand. Outside Canada and Israel, international net revenue also hit a record, growing 88% year over year on strong German flower demand. In Canada, Spinach stayed the number one vape brand for a second straight quarter and the number one edibles brand for an eighth straight quarter, pushing its national market share to 5.9% and making it the country’s second largest cannabis brand overall. Management backed the numbers with capital return, repurchasing 12.3 million shares in the first half of 2026 while holding $827 million in cash, deposits and short-term investments.
An Old Fight Reopens
The Israel growth story now carries a legal overhang. In June, Israel’s Trade Levies Commissioner opened a new investigation into alleged dumping of Canadian medical cannabis, following a 2024 probe that closed without any duty imposed. That inquiry was terminated on procedural grounds on July 28, but a fresh complaint was filed just two days later, on July 30, and the Commissioner confirmed a new investigation into Cronos on August 5. Cronos disputes the allegations, but it cannot predict how long the process runs or whether a duty eventually lands on the products feeding its best-performing market.
The balance sheet shifted too. Cash and cash equivalents alone fell 41% year over year to $467 million, even as the company moved funds into short-term investments, and capital expenditures dropped 54% to $1.8 million for the quarter. Cronos is still waiting to close its acquisition of CanAdelaar B.V., pending Dutch regulatory clearance, with no firm date beyond a second half 2026 target. Part of the swing to net income also came from foreign currency transaction gains rather than the core business alone, a reminder that not every dollar of the turnaround is repeatable.
What The Market Is Pricing
Hedge fund interest in Cronos ticked up to 17 funds holding a position last quarter from 16 the quarter before, a modest gain in institutional conviction. Short interest sits at just 1.78% of float, pointing to little organized skepticism against the stock right now. Shares trade at a forward P/E of 26.04, as of September 11, a multiple that assumes the recent growth and margin expansion keeps going rather than fades. Rising fund interest, light shorting, and a premium multiple together suggest the market has already given Cronos credit for this quarter’s turnaround.
The Open Question Ahead
Cronos closed the quarter with growth, profitability and market share gains all lining up at once, a combination that had eluded the company for years. But the reopened Israeli trade investigation lands directly on the market fueling most of that growth, and its timeline sits entirely outside Cronos’ control. For the turnaround to hold, Israel and the international business need to keep expanding even if a duty eventually gets imposed.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
